Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

United Therapeutics (UTHR) EBT (2016 - 2025)

Historic EBT for United Therapeutics (UTHR) over the last 17 years, with Q3 2025 value amounting to $438.0 million.

  • United Therapeutics' EBT rose 1271.23% to $438.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 billion, marking a year-over-year increase of 1589.12%. This contributed to the annual value of $1.5 billion for FY2024, which is 2077.22% up from last year.
  • Latest data reveals that United Therapeutics reported EBT of $438.0 million as of Q3 2025, which was up 1271.23% from $408.4 million recorded in Q2 2025.
  • United Therapeutics' EBT's 5-year high stood at $438.0 million during Q3 2025, with a 5-year trough of $32.5 million in Q1 2021.
  • Moreover, its 5-year median value for EBT was $312.5 million (2022), whereas its average is $296.2 million.
  • In the last 5 years, United Therapeutics' EBT tumbled by 8106.06% in 2021 and then surged by 84984.62% in 2022.
  • Over the past 5 years, United Therapeutics' EBT (Quarter) stood at $140.5 million in 2021, then increased by 27.26% to $178.8 million in 2022, then surged by 65.21% to $295.4 million in 2023, then skyrocketed by 34.22% to $396.5 million in 2024, then rose by 10.47% to $438.0 million in 2025.
  • Its EBT stands at $438.0 million for Q3 2025, versus $408.4 million for Q2 2025 and $423.5 million for Q1 2025.